Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.

Author Department

Medicine; Pathology

Document Type

Article, Peer-reviewed

Publication Date

3-1-2006

Abstract

Rituximab is a chimeric monoclonal antibody that recognizes the CD20 antigen and is used to treat B-cell non-Hodgkin lymphoma (B-NHL). Few studies have been published examining the use of antibody panels to evaluate B-NHL treated with rituximab. The autho

Publication ISSN

0894-1130

Share

COinS